G2GBIO Inc.

G2GBIO Inc. is a clinical-stage biotechnology company that develops pharmaceutical products. Its pipeline includes GB-5001, GB-5001A, and GB-5112 for Alzheimer's disease; GB-6002, an opioid for post-operative pain; GB-7001 for type-2 diabetes; GB-5313 for osteoarthritis; GB-7101 and GB-7103 for prostate cancer; GB-6201 and GB-6203 for androgenetic alopecia; and GH-001 for hepatitis B. It also develops GB-2001 for animal castration and GB-2006, an animal post-operative pain relief drug in clinical trials. Founded in 2017, the company is headquartered in Cheongju-si, South Korea.